Cibus narrows Q3 loss to $21.9 million but cash covers operations only into early 2027
GlobeNewswire · · AI-summarised by FinFlash
Gene-editing firm Cibus reported a third-quarter net loss of $21.9 million, or $0.29 per Class A share, narrower than $24.3 million a year earlier, as R&D spending fell to $7.9 million from The short cash runway points to near-term financing or dilution risk for Cibus shareholders; watch for capital-raising announcements. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context